Following on from information provided to NICE by the company in November 2018, the appraisal of Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 997 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 November 2022 | Discontinued. Following on from information provided to NICE by the company in November 2018, the appraisal of Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 November 2018 | Suspended. As you will be aware the Department for Health and Social Care has asked NICE to carry out an appraisal of ibrutinib combination therapy for untreated diffuse large B-cell lymphoma. However, the company have advised that they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes |
| 17 September 2018 - 15 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 05 December 2017 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual